fda stops semaglutide warning approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease FDA's Removal of Semaglutide and

Additionally, reports from the CDC link damp buildings with increased risks for respiratory irritation, fatigue, and immune dysfunctionsymptoms that align closely with mold-triggered MCAS

Let's use its IUPAC name

Direct Meds and the 2026 Insurance Coverage Loss Landscape Why 24 Million Americans Are Searching for GLP-1 Like Direct Meds Right Now Between 2025 and 2026 an estimated 24 million Americans lost insurance coverage for GLP-1 medications as major pharmacy benefit managers dropped GLP-1s from their formularies and employers restructured health benefits to manage pharmacy cost growth

Lisa McCormack Lisa July 26, 2026 Underwhelmed I am a month in and have noticed NONE of the benefits mentioned in the ads